Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ACHILLES THERAPEUTICS PLC

(ACHL)
  Rapport
Vertraagde tijd Nasdaq  -  22:00 30-09-2022
2.260 USD   -7.76%
23/09Europese ADR's dalen in de vrijdaghandel
MT
09/08Achilles Therapeutics plc rapporteert winstresultaten voor het tweede kwartaal en de zes maanden eindigend op 30 juni 2022
CI
30/06Achilles Therapeutics plc kondigt managementbenoemingen aan, met ingang van 1 juli 2022
CI
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciënConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiële publicatiesSectornieuws
Communiqués de presse de la société ACHILLES THERAPEUTICS PLC
09/08Achilles Therapeutics : Reports Second Quarter 2022 Financial Results and Recent Business ..
PU
09/08Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business..
GL
25/07Achilles Therapeutics : Cell Therapy Potency Assay Summit
PU
21/07Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized ..
AQ
30/06Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, ..
AQ
28/06Achilles Therapeutics : Results of Annual General Meeting - Form 6-K
PU
21/06Achilles Therapeutics Recognized with the 2022 PING Innovation Award
AQ
26/05Achilles Therapeutics : THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION -..
PU
10/05Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business ..
AQ
09/05Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON T..
AQ
04/05Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors
GL
03/05Achilles Therapeutics to Present at Upcoming Conferences
GL
12/04The Center for Breakthrough Medicines (CBM) Strikes Multi-Year Deal with UK Cell Therap..
PR
12/04Achilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for M..
AQ
05/04Achilles Therapeutics to Present at Upcoming Conferences
AQ
04/04Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from..
AQ
08/03Achilles Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
AQ
01/03Achilles Therapeutics Selects Netrality's 401 North Broad for United States Headquarter..
AQ
01/03Achilles Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Re..
AQ
07/02Achilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena G..
AQ
13/01Achilles Therapeutics Provides Business Update and Outlook for 2022
AQ
10/01Achilles Therapeutics : Corporate Presentation - January 2022
PU
2021Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021Esmo Io 2021 Poster 58p : Achilles VELOS Process 2 generates a >10-fold improvement in cNe..
PU
2021Achilles Post-SITC Review and Corporate Update
PU
2021Sitc 2021 Poster 193 : The Achilles VELOSTM Process 2 boosts the dose of highly functional..
PU
2021Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business ..
PU
2021Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business ..
GL
2021Sitc 2021 Poster 543 : Sensitive quantification and tracking of the active components of c..
PU
2021Esgct 2021 Or54 : Multicentre, prospective research protocol for development of a clonal n..
PU
2021Achilles Therapeutics : Presents Data at the 2021 European Society for Gene and Cell Thera..
AQ
2021Achilles Therapeutics : to join the Northern Alliance Advanced Therapy Treatment Centre co..
AQ
2021Achilles Therapeutics : to Present at Upcoming Scientific Congresses
AQ
2021Achilles Therapeutics : to Present at Upcoming Investor Conferences
AQ
2021Achilles Therapeutics : Announces Grant of US and European Patents
AQ
2021Achilles Therapeutics : Reports Second Quarter 2021 Financial Results and Recent Business ..
PU
2021Achilles Therapeutics : Reports Second Quarter 2021 Financial Results and Recent Business ..
AQ
2021Achilles Therapeutics : Enrolls First US Patient in Ongoing Phase I/IIa Study in Advanced ..
AQ
2021Achilles Therapeutics : Results of Annual General Meeting (Form 6-K)
PU
2021Achilles Therapeutics : Details Phase I/IIa Clinical Trial Design of CHIRON in Patients wi..
AQ
2021Achilles Therapeutics : THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION (..
PU
2021Achilles Therapeutics : Reported first clinical data from the CHIRON and THETIS trials and..
PU
2021Achilles Therapeutics Reports First Quarter 2021 Financial Results and Recent Business ..
GL
2021Achilles Therapeutics Receives Horizon 2020 Grant as Part of Neoantigen Consortium
GL
2021Achilles Therapeutics to present at the BofA Securities 2021 Virtual Healthcare Confere..
GL
2021Achilles Therapeutics : Appoints Julie O'Neill to Board of Directors and Markwin Velders, ..
PU
2021Achilles Therapeutics Appoints Julie O'Neill to Board of Directors and Markwin Velders,..
GL
2021Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Trac..
GL
2021Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering
GL
Volgende evenement op ACHILLES THERAPEUTICS PLC